沛嘉医疗(09996.HK)上年度收入增最多42.8%

阿斯达克财经
10 Feb

沛嘉医疗(09996.HK) 公布去年度未经审核营运数据,截至2024年12月31日止,全年收入预期达到约6.1亿至6.3亿元人民币,按年增幅介乎38.3%至42.8%,主要归因于期内集团所有神经介入产品线的持续快速增长,以及在中国经导管主动脉瓣置换市场的份额扩大。

过往派息
公布日期派息事项派息内容
2024/08/23中期业绩无派息
2024/03/28末期业绩无派息
2023/08/31中期业绩无派息
2023/03/31末期业绩无派息

通过持续致力于市场教育及开发,沛嘉医疗不断扩大其第一代及第二代TAVR产品的市场份额,去年TaurusOne及TaurusElite在150多间新医院中获得采用,全年合计植入超过3,400台,于去年底集团的TAVR产品已累计覆盖近650间医院。(gc/u)(港股报价延迟最少十五分钟。)
AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10